Living-donor lobar lung transplantation for pulmonary complications after hematopoietic stem cell transplantation

Masaomi Yamane, Yoshifumi Sano, Shinichi Toyooka, Megumi Okazaki, Hiroshi Date, Takahiro Oto

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND.: The indication of lung transplantation for patients with pulmonary complications of hematopoietic stem cell transplantation (HSCT) remains controversial, and only few such cases have been reported. We reviewed our experiences regarding living-donor lobar lung transplantation (LDLLT) in patients with pulmonary complications of HSCT. METHODS.: We reviewed and assessed seven patients (age, 6-45 yr) who underwent LDLLT at Okayama University Hospital for pulmonary complications of HSCT (HSCT group). Their characteristics and postoperative results were compared with those of 41 LDLLT without HSCT patients (non-HSCT group). In the HSCT group, indications for LDLLT included bronchiolitis obliterans (n=6) and pulmonary fibrosis (n=1) that had developed after treatments involving HSCT. Preexisting hematologic diseases included acute lymphocyte leukemia (n=4), acute promyelocystic leukemia (n=1), myelodysplastic syndrome (n=1), and aplastic anemia (n=1). RESULTS.: In the HSCT group, two patients died due to infectious complications, whereas five are currently alive (an overall survival of 71.4%) without any recurrence of the hematologic diseases (mean follow-up period, 35.7 months). The mean of acute rejection episodes was 1.1 per patient in the HSCT group and 1.8 in the non-HSCT group. One of the seven HSCT (14.4%) and 10 non-HSCT (24.4%) patients have currently developed bronchiolitis obliterans syndrome. CONCLUSION.: Our results showed that LDLLT for patients with respiratory failure because of pulmonary complications of HSCT could be an effective approach with less rejection episodes; however, it has a possibly higher risk of the development of infectious complications.

Original languageEnglish
Pages (from-to)1767-1770
Number of pages4
JournalTransplantation
Volume86
Issue number12
DOIs
Publication statusPublished - Dec 27 2008

Fingerprint

Lung Transplantation
Living Donors
Hematopoietic Stem Cell Transplantation
Lung
Stem Cell Transplantation
Bronchiolitis Obliterans
Hematologic Diseases
Leukemia
Preexisting Condition Coverage
Aplastic Anemia
Pulmonary Fibrosis
Myelodysplastic Syndromes
Respiratory Insufficiency
Lymphocytes
Recurrence

Keywords

  • Bone marrow transplantation
  • Bronchiolitis obliterans
  • Living-donor lobar lung transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Living-donor lobar lung transplantation for pulmonary complications after hematopoietic stem cell transplantation. / Yamane, Masaomi; Sano, Yoshifumi; Toyooka, Shinichi; Okazaki, Megumi; Date, Hiroshi; Oto, Takahiro.

In: Transplantation, Vol. 86, No. 12, 27.12.2008, p. 1767-1770.

Research output: Contribution to journalArticle

@article{015ecdc7c07e40279ca59bc32d59efa2,
title = "Living-donor lobar lung transplantation for pulmonary complications after hematopoietic stem cell transplantation",
abstract = "BACKGROUND.: The indication of lung transplantation for patients with pulmonary complications of hematopoietic stem cell transplantation (HSCT) remains controversial, and only few such cases have been reported. We reviewed our experiences regarding living-donor lobar lung transplantation (LDLLT) in patients with pulmonary complications of HSCT. METHODS.: We reviewed and assessed seven patients (age, 6-45 yr) who underwent LDLLT at Okayama University Hospital for pulmonary complications of HSCT (HSCT group). Their characteristics and postoperative results were compared with those of 41 LDLLT without HSCT patients (non-HSCT group). In the HSCT group, indications for LDLLT included bronchiolitis obliterans (n=6) and pulmonary fibrosis (n=1) that had developed after treatments involving HSCT. Preexisting hematologic diseases included acute lymphocyte leukemia (n=4), acute promyelocystic leukemia (n=1), myelodysplastic syndrome (n=1), and aplastic anemia (n=1). RESULTS.: In the HSCT group, two patients died due to infectious complications, whereas five are currently alive (an overall survival of 71.4{\%}) without any recurrence of the hematologic diseases (mean follow-up period, 35.7 months). The mean of acute rejection episodes was 1.1 per patient in the HSCT group and 1.8 in the non-HSCT group. One of the seven HSCT (14.4{\%}) and 10 non-HSCT (24.4{\%}) patients have currently developed bronchiolitis obliterans syndrome. CONCLUSION.: Our results showed that LDLLT for patients with respiratory failure because of pulmonary complications of HSCT could be an effective approach with less rejection episodes; however, it has a possibly higher risk of the development of infectious complications.",
keywords = "Bone marrow transplantation, Bronchiolitis obliterans, Living-donor lobar lung transplantation",
author = "Masaomi Yamane and Yoshifumi Sano and Shinichi Toyooka and Megumi Okazaki and Hiroshi Date and Takahiro Oto",
year = "2008",
month = "12",
day = "27",
doi = "10.1097/TP.0b013e318190b0be",
language = "English",
volume = "86",
pages = "1767--1770",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Living-donor lobar lung transplantation for pulmonary complications after hematopoietic stem cell transplantation

AU - Yamane, Masaomi

AU - Sano, Yoshifumi

AU - Toyooka, Shinichi

AU - Okazaki, Megumi

AU - Date, Hiroshi

AU - Oto, Takahiro

PY - 2008/12/27

Y1 - 2008/12/27

N2 - BACKGROUND.: The indication of lung transplantation for patients with pulmonary complications of hematopoietic stem cell transplantation (HSCT) remains controversial, and only few such cases have been reported. We reviewed our experiences regarding living-donor lobar lung transplantation (LDLLT) in patients with pulmonary complications of HSCT. METHODS.: We reviewed and assessed seven patients (age, 6-45 yr) who underwent LDLLT at Okayama University Hospital for pulmonary complications of HSCT (HSCT group). Their characteristics and postoperative results were compared with those of 41 LDLLT without HSCT patients (non-HSCT group). In the HSCT group, indications for LDLLT included bronchiolitis obliterans (n=6) and pulmonary fibrosis (n=1) that had developed after treatments involving HSCT. Preexisting hematologic diseases included acute lymphocyte leukemia (n=4), acute promyelocystic leukemia (n=1), myelodysplastic syndrome (n=1), and aplastic anemia (n=1). RESULTS.: In the HSCT group, two patients died due to infectious complications, whereas five are currently alive (an overall survival of 71.4%) without any recurrence of the hematologic diseases (mean follow-up period, 35.7 months). The mean of acute rejection episodes was 1.1 per patient in the HSCT group and 1.8 in the non-HSCT group. One of the seven HSCT (14.4%) and 10 non-HSCT (24.4%) patients have currently developed bronchiolitis obliterans syndrome. CONCLUSION.: Our results showed that LDLLT for patients with respiratory failure because of pulmonary complications of HSCT could be an effective approach with less rejection episodes; however, it has a possibly higher risk of the development of infectious complications.

AB - BACKGROUND.: The indication of lung transplantation for patients with pulmonary complications of hematopoietic stem cell transplantation (HSCT) remains controversial, and only few such cases have been reported. We reviewed our experiences regarding living-donor lobar lung transplantation (LDLLT) in patients with pulmonary complications of HSCT. METHODS.: We reviewed and assessed seven patients (age, 6-45 yr) who underwent LDLLT at Okayama University Hospital for pulmonary complications of HSCT (HSCT group). Their characteristics and postoperative results were compared with those of 41 LDLLT without HSCT patients (non-HSCT group). In the HSCT group, indications for LDLLT included bronchiolitis obliterans (n=6) and pulmonary fibrosis (n=1) that had developed after treatments involving HSCT. Preexisting hematologic diseases included acute lymphocyte leukemia (n=4), acute promyelocystic leukemia (n=1), myelodysplastic syndrome (n=1), and aplastic anemia (n=1). RESULTS.: In the HSCT group, two patients died due to infectious complications, whereas five are currently alive (an overall survival of 71.4%) without any recurrence of the hematologic diseases (mean follow-up period, 35.7 months). The mean of acute rejection episodes was 1.1 per patient in the HSCT group and 1.8 in the non-HSCT group. One of the seven HSCT (14.4%) and 10 non-HSCT (24.4%) patients have currently developed bronchiolitis obliterans syndrome. CONCLUSION.: Our results showed that LDLLT for patients with respiratory failure because of pulmonary complications of HSCT could be an effective approach with less rejection episodes; however, it has a possibly higher risk of the development of infectious complications.

KW - Bone marrow transplantation

KW - Bronchiolitis obliterans

KW - Living-donor lobar lung transplantation

UR - http://www.scopus.com/inward/record.url?scp=58849152832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849152832&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e318190b0be

DO - 10.1097/TP.0b013e318190b0be

M3 - Article

C2 - 19104419

AN - SCOPUS:58849152832

VL - 86

SP - 1767

EP - 1770

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -